Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Apremilast Efficacy Results Disappoint But May Be Enough For Commercial Success

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Celgene’s PDE-4 inhibitor met the primary endpoint in the first of two pivotal psoriasis trials, but analysts worried that the treatment effect was less than that seen in a Phase II study. Some analysts see a niche for apremilast in treatment-naïve patients before they move on to biologic therapy. Celgene aims to begin apremilast regulatory filings this autumn, first targeting psoriatic arthritis.


Related Content


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts